Marker Therapeutics

MRKR Lead: Phase 1 ★ Read the deep dive → 7 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-15

Catalyst timeline

Corporate cash runway update2Q 2027Corporate cash runway update, 2Q 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

MT-601

Cell Target: NY-ESO-1, PRAME, MAGE-A4, Survivin, WT1, SSX2

MT-401-OTS

Cell Target: WT1, NY-ESO-1, PRAME, Survivin

Technology platforms

MAR-T · Baylor College of Medicine

Multi Antigen Recognizing T cell platform that selectively expands natural tumor-specific T cells from a patient's or donor's blood to recognize a broad range of tumor-associated antigens without genetic modification; applicable to hematological malignancies and solid tumors

Targets: NY-ESO-1, PRAME, MAGE-A4, Survivin, WT1, SSX2

Biotech Distilled coverage (7)

2026-08-15 UPDATE: Marker Therapeutics (MRKR) - The Catalyst That Didn’t Show Up 🔒 Paid
2026-05-16 UPDATE: Marker Therapeutics (MRKR) - Q1 Numbers, Stretched Runway, Stretched Vendors 🔒 Paid
2026-05-04 UPDATE: Marker Therapeutics (MRKR) - The Dilution Cannon Gets Loaded
2026-04-01 CORRECTION: Marker Therapeutics (MRKR) - MRKR’s Dilution Trap is Actually Bigger Than I Thought
2026-03-22 UPDATE: Marker Therapeutics (MRKR) - 10-K & Definitive Proxy Drop 🔒 Paid
2026-03-15 UPDATE: Marker Therapeutics (MRKR) - The Dilution Gap Becomes a Reality 🔒 Paid
2026-03-10 Marker Therapeutics (MRKR) - Scientific Deep Dive for and MT-601 and Pipeline Products

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.